✨ Free AI Report
Athira Pharma, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Athira Pharma, Inc.
Company Research

Athira Pharma, Inc.: Business Overview, Financials & Competitive Analysis

Athira Pharma, Inc. scores 4/10 on the AskCyborg Cyborg Score (Challenged). Early-stage neurodegenerative disease biotech at inflection point with viable pipeline but severe capital constraints and reputational headwinds requiring strategic combination. Current market capitalization is $16.5M with cash, cash equivalents and investments of $25.2 million as of September 30, 2025. In 2025, the company paid a $4 million settlement relating.

What is Athira Pharma, Inc.'s industry? Athira Pharma, Inc. (athira.com) operates in Biopharmaceutical / Drug Discovery - Neurodegenerative Disease Focus. AskCyborg classifies Athira Pharma, Inc. under Biopharmaceutical / Drug Discovery - Neurodegenerative Disease Focus in its company registry.

Athira Pharma is a late clinical stage American biopharmaceutical company developing small-molecule therapeutics targeting neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's ...

4/ 10Challenged

Cyborg Score thesis

Early-stage neurodegenerative disease biotech at inflection point with viable pipeline but severe capital constraints and...

Read the full analyst-debate transcript →
Industry Biopharmaceutical / Drug Discovery - Neurodegenerative Disease Focus
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 2, 2026
AI-Generated Research
30+ Page Report

Get the Latest Athira Pharma, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Athira Pharma, Inc.

AskCyborg analysts argue the bull and bear cases for Athira Pharma, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Athira Pharma, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Athira Pharma, Inc. Overview

Pro stress-test →

Athira Pharma is a late clinical stage American biopharmaceutical company developing small-molecule therapeutics targeting neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's drug development pipeline includes potential first-in-class and next-generation novel small molecule drug candidates designed to promote the neurotrophic hepatocyte growth factor (HGF) system, which activates neuroprotective, neurotrophic and anti-inflammatory pathways in the central nervous system.

Strategic Profile

Pro stress-test →

Athira is on track to enable dosing ALS patients in 2025. Athira continues to explore strategic alternatives focused on maximizing stockholder value after receiving topline results from its Phase 2/3 LIFT-AD clinical trial in September 2024. The company faces resource constraints and has undertaken significant cost restructuring.

Competitive Landscape

Pro stress-test →

Cassava Sciences, Cognition Therapeutics, Quince Therapeutics, Alzheon, and Neuphoria Therapeutics are among 15 competitors in the neurodegenerative disease drug development space. Athira competes in a crowded market with limited resources relative to better-capitalized rivals.

Industry Context

Athira Pharma, Inc. operates in Biopharmaceutical / Drug Discovery - Neurodegenerative Disease Focus.

Key facts

Founded: 2011 · Headquarters: Bothell, WA · Employees: 26 · Market cap: $16.5M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Athira Pharma, Inc..

  • ATH-1105 demonstrated a favorable safety profile and was well-tolerated in healthy volunteers, supporting continued clinical development.
  • Cash position declined from $51.3M (end of 2024) to $25.2M (September 30, 2025), with Q3 2025 showing reduced quarterly burn rate.
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • December 2025Announced exclusive license to Lasofoxifene Phase 3 development program for metastatic breast cancer and financing for up to $236 million
  • November 2025Completed Phase 1 clinical study of ATH-1105 in healthy volunteers with favorable safety profile
  • +2 moreTrack every material event for Athira Pharma, Inc. as it happens. Explore monitoring →
Get alerted when Athira Pharma, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Cassava SciencesAlzheimer's disease therapeutics→Cognition TherapeuticsNeurodegenerative disease treatments→Quince TherapeuticsNeurodegenerative disease focus→

Compare Athira Pharma, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Athira Pharma, Inc. operates in Biopharmaceutical / Drug Discovery - Neurodegenerative Disease Focus. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biopharmaceutical by Cyborg Score

Browse Biopharmaceutical / Drug Discovery - Neurodegenerative Disease Focus research →
NEW · MCP server

Ask your AI assistant about Athira Pharma, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Athira Pharma, Inc. and its top competitor on Cyborg Score”
“What did Athira Pharma, Inc. do this quarter?”
“Is Athira Pharma, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Athira Pharma, Inc. do?+
Athira Pharma is a late clinical stage American biopharmaceutical company developing small-molecule therapeutics targeting neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's ...
What is Athira Pharma, Inc.'s Cyborg Score?+
Athira Pharma, Inc. has a Cyborg Score of 4/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Athira Pharma, Inc.'s main competitors?+
Named competitors include Cassava Sciences, Cognition Therapeutics, Quince Therapeutics. The full competitive landscape is in the AskCyborg report.
How can I get the full Athira Pharma, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Athira Pharma, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Athira Pharma, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical research

Companies in the same sector and named competitors, ranked by Cyborg Score.

9Eli Lilly and Company8argenx SE8Ascendis Pharma A/S8Avidity Biosciences, Inc.8BeOne Medicines AG8Celltrion, Inc.8Corcept Therapeutics Incorporated8Insmed Incorporated8Roivant Sciences Ltd.8Terns Pharmaceuticals, Inc.Top companies in Biopharmaceutical by Cyborg Score